Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,418 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT06964906RecruitingPhase 2
HIFU, immunotherapy, and chemo for ER+ HER2- breast cancer
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
Hangzhou, ZhejiangAges 18–75 - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06962163Recruiting
PET scan study for metastatic triple negative breast cancer
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
Saint-HerblainAges 18 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06911970Recruiting
Exercise and immune response in cancer treatment
This trial tests whether aerobic exercise can help your immune system fight cancer better during chemotherapy or immunotherapy. It is for people with breast or colon cancer that has not spread to other parts of the body.
Sherbrooke, QuebecAges 40–70 - NCT06914661Enrolling by invitation
DS8201 for metastatic breast cancer: a real-world study
This trial looks at the safety and effectiveness of DS8201 in people with metastatic breast cancer (cancer that has spread to other parts of the body). Doctors will review medical records to see how well the drug works and how safe it is.
Changchun, JilinAges 18–100 - NCT06879704Recruiting
Predicting breast cancer response to pre-surgery therapy with X-rays
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
RouenAges 18–75 - NCT06833853Recruiting
Blood test study for women with advanced breast cancer
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06831955RecruitingPhase 2
Lifestyle program to boost chemo before breast cancer surgery
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
AntwerpAges 18 years+ - NCT05804578Recruiting
Blood test monitoring for metastatic breast cancer treatment
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
Kingston, OntarioAges 18 years+ - NCT06765707Enrolling by invitation
Monitoring symptoms to improve medication use in breast cancer
This trial tests if tracking how you feel and reporting your symptoms can help women with hormone receptor-positive breast cancer take their hormone-blocking medication more consistently. It may be a good fit if you have been prescribed aromatase inhibitors or similar therapy and have had trouble taking it as directed.
Chicago, IllinoisAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06706557Recruiting
Studying tumor DNA in HER2-low advanced breast cancer
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
Milan, MIAges 18 years+ - NCT06697158Recruiting
Lymphedema therapy and its effect on sleep and quality of life
This study tests a treatment called complex decongestive physiotherapy for women who have swelling in one arm after breast cancer surgery. It looks at whether this therapy can improve their sleep and overall quality of life.
BoluAges 18–85 - NCT06603597Recruiting
HER2-positive breast cancer registry
This registry tracks people with HER2-positive breast cancer to learn more about the disease and how it's treated. You can join at any stage of cancer.
Overland Park, KansasAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
San Francisco, CaliforniaAges 18 years+ - NCT06512558Recruiting
Using augmented reality for breast cancer surgery planning
This trial tests whether augmented reality can help doctors locate tumors that cannot be felt during breast cancer surgery. If you are having surgery for a non-palpable breast lesion and need an MRI, you may be able to join.
Clermont-FerrandAges 18–100 - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+ - NCT04254263RecruitingPhase 3
Pyrotinib after breast cancer therapy for HER2-positive early disease
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,418 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.